CLPT News & Events

ClearPoint Neuro announced the successful completion of the first clinical procedure utilizing the 510(k)-cleared Velocity Alpha MR High Speed Surgical Drill System. "The design of the drill bits provides tactile feedback during bone access, and facilitates consistent, predictable opening of the skull even during minimally invasive procedures where the bone is not fully visualized," said Paul Larson, chief medical officer of ClearPoint Neuro. "For my cases that involve multiple trajectories, its integration with the SmartFrame platform has the potential to reduce my procedure times by an hour or more."

ClearPoint Neuro announced receipt of a Medical Device License from Health Canada for its Neuro Navigation System, further expanding our Drug Delivery ecosystem and global footprint. Covering both ClearPoint MRI-guidance and new iCT-guidance workflows in Canada, the MDL builds on the previously announced therapy delivery product clearance for the SmartFlow Neuro Cannula received in October 2025. This milestone reinforces ClearPoint's role as a global leader in integrated navigation and therapy delivery solutions and will enable the Company's biopharma partners to operate Canadian clinical trial and commercial sites using the same platform and standardized workflow already in use in the United States.